IP Library Granted Patent US 8,071,550
Granted Patent B2
US 8,071,550 · App. 10/379,157 · Granted Dec 6, 2011

Methods for treating uterine disorders

Assignee: Allergan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,550
App. No.
10/379,157
Granted
Dec 6, 2011
Kind
B2
Abstract

A method for treating uterine disorders, including hyperplasic, hypertonic, cystic and/or neoplastic uterine gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted uterine tissue.

Claims (8)

1. A method for treating a uterine fibroid, the method comprising the step of local administration of between about 10 −3 U/kg and about 2000 U/kg of a native, unmodified botulinum toxin that is not conjugated to a targeting moiety, to the uterine fibroid, thereby treating the uterine fibroid.

2. The method of claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

3. The method of claim 1 , wherein the botulinum toxin is botulinum toxin is botulinum toxin type A.

4. The method of claim 1 , wherein the botulinum toxin is administered in an amount of between about 10 −2 U/kg and about 200 U/kg.

5. The method of claim 1 , wherein the botulinum toxin is administered in an amount of between about 10 −1 U/kg and about 35 U/kg.

6. The method of claim 1 , wherein treating the uterine fibroid further reduces the distortion of the endometrial cavity.

7. The method of claim 1 , wherein treating the uterine fibroid further reduces the frequency of miscarriages.

8. The method of claim 1 , wherein treating the uterine fibroid further prevents the fibroid from becoming malignant.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2003
From: SCHIFFMAN, RHETT M.
To: ALLERGAN, INC.
Reel/Frame 013856/0102 →
Continuity (1)
Related Publication 20040175399A1 · Sep 9, 2004